Business Context and Reporting Period
This Form 8-K Current Report was filed by Aeglea BioTherapeutics, Inc. (AGLE) on September 7, 2023. The filing details a material modification to the rights of security holders, specifically the implementation of a 1-for-25 reverse stock split and a reduction in authorized common stock. The effective time for these changes was 12:01 a.m. Eastern Time on September 8, 2023.
Key Financial Metrics
The filing provides selected historical financial data restated to reflect the reverse stock split. The company reported net losses for the three most recent fiscal years. The filing does not provide current revenue, cash flow, debt, or liquidity figures in this specific report.
| Year Ended Dec 31 | 2022 | 2021 | 2020 |
|---|---|---|---|
| Net Loss (in thousands) | $(83,815) | $(65,801) | $(80,893) |
| Net Loss Per Share (Basic & Diluted) | $(24.86) | $(25.02) | $(37.89) |
| Weighted-Average Shares Outstanding | 3,371,231 | 2,629,784 | 2,134,869 |
Note: Share counts and per-share data are adjusted to give effect to the 1-for-25 reverse stock split. The split had no effect on the reported net loss amounts.
Material Changes
- Reverse Stock Split: Every 25 shares of common stock were combined into one new share. No fractional shares were issued; instead, fractional interests were aggregated and sold, with proceeds distributed in cash.
- Authorized Shares Reduction: The total number of authorized common shares was reduced from 500,000,000 to 20,000,000.
- Trading Adjustments: Common stock began trading on a split-adjusted basis on September 8, 2023, under a new CUSIP number (00773J202).
- Capitalization Update: As of June 22, 2023, the company's adjusted total capitalization (including all common equivalents on an as-converted basis) was approximately 47.7 million shares.
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, management commentary on future operations, or specific risk factors beyond the standard disclosures regarding the stock split mechanics. The company noted that proportionate adjustments were made to the conversion ratio of Series A preferred stock, outstanding warrants, and equity awards to reflect the reverse split ratio.
Investor Verification Checklist
- Verify the new CUSIP number (00773J202) for trading purposes.
- Confirm the cash settlement amount for any fractional shares held prior to the split.
- Review the updated terms of outstanding warrants and equity awards to ensure exercise prices and share counts were correctly adjusted.
- Check the company's latest Form 10-K or 10-Q for current liquidity and cash position, as this 8-K only provides historical loss data.